Autonomix Medical to Present New Long-Term Pain Mitigation Data in Pancreatic Cancer at SSO 2026 Annual Meeting
ByAinvest
Thursday, Feb 19, 2026 8:31 am ET1min read
AMIX--
Autonomix Medical will present new long-term pain mitigation data in pancreatic cancer at the Society of Surgical Oncology (SSO) 2026 Annual Meeting. The presentation, titled "Pain Mitigation in Pancreatic Adenocarcinoma," has been accepted as an oral podium presentation. The data highlights the potential of Autonomix Medical's minimally invasive transvascular RF energy-based approach to address chronic pain in pancreatic cancer patients. The SSO Annual Meeting convenes leading surgical oncologists and healthcare professionals to showcase advances in surgical oncology.

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue



Comments
No comments yet